Odefsey (Emtricitabine, Tenofovir Alafenamide, Rilpivirine)

Emtricitabine, the active ingredient in Odefsey, is a nucleoside reverse transcriptase inhibitor presented as a fixed-dose combination tablet for oral use. It treats HIV-1 infection in adults and adolescents. GNH USA supplies Odefsey as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Odefsey as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Odefsey is a fixed‑dose combination antiretroviral therapy used in the management of HIV‑1 infection.

- HIV‑1 infection in treatment‑naïve adults: improves viral suppression and CD4+ count. - HIV‑1 infection in treatment‑naïve adolescents (12 years and older): provides a complete regimen in a single tablet. - HIV‑1 infection in patients with prior virologic suppression on a compatible regimen: maintains viral control when switching to a single‑pill regimen.

Adverse reactions to Odefsey are reported across a range of frequencies.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: generalised tiredness. - Diarrhoea: loose stools, usually self‑limiting. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated transaminases or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Lactic acidosis: metabolic acidosis with elevated lactate. - Renal toxicity: worsening kidney function, especially in patients with pre‑existing impairment. - QT‑interval prolongation: cardiac conduction changes detectable on ECG.

When prescribing Odefsey, clinicians should consider several safety aspects.

- Renal function: assess baseline creatinine clearance before initiating therapy. - Hepatic function: monitor liver enzymes in patients with hepatitis or alcohol use. - Pregnancy: weigh benefits against potential risks; consult current guidelines. - Concomitant medications: review for drugs that may affect rilpivirine plasma levels. - Adherence: emphasize the importance of daily dosing for viral suppression. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Odefsey may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Antacids containing aluminium or magnesium: reduce rilpivirine absorption. - Proton pump inhibitors (e.g., omeprazole): markedly decrease rilpivirine exposure. - Rifampicin: induces metabolism leading to sub‑therapeutic rilpivirine levels.

Moderate Interactions (Monitor Closely): - HMG‑CoA reductase inhibitors (statins): may increase statin concentrations. - Warfarin: potential alteration of anticoagulant effect. - Contraceptive hormones: possible reduction in hormonal efficacy.